Shared on04 Aug 25Fair value Increased 25%
Upward revisions in Alnylam Pharmaceuticals’ net profit margin and revenue growth forecasts have driven a significant increase in the consensus analyst price target from $339.27 to $421.64. What's in the News Alnylam raised its full-year 2025 revenue guidance to $2.65 billion–$2.8 billion from the prior range of $2.05 billion–$2.25 billion.
Shared on30 Apr 25Fair value Decreased 0.49%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 1.75%
AnalystConsensusTarget has decreased future PE multiple from 62.1x to 52.4x and decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on16 Apr 25Fair value Increased 0.27%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.87%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 2.09%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 0.089%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 7.33%
AnalystConsensusTarget has increased revenue growth from 25.8% to 28.8%.